196 related articles for article (PubMed ID: 20038957)
21. Catalog of 77 single-nucleotide polymorphisms (SNPs) in the carbohydrate sulfotransferase 1 (CHST1) and carbohydrate sulfotransferase 3 (CHST3) genes.
Iida A; Saito S; Sekine A; Mishima C; Kitamura Y; Kondo K; Harigae S; Osawa S; Nakamura Y
J Hum Genet; 2002; 47(1):14-9. PubMed ID: 11829137
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD
J Clin Oncol; 2004 Jul; 22(13):2532-9. PubMed ID: 15226321
[TBL] [Abstract][Full Text] [Related]
23. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
24. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
Hahn NM; Marsh S; Fisher W; Langdon R; Zon R; Browning M; Johnson CS; Scott-Horton TJ; Li L; McLeod HL; Sweeney CJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6094-9. PubMed ID: 17062685
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
Tu SM; Mathew P; Wong FC; Jones D; Johnson MM; Logothetis CJ
J Clin Oncol; 2009 Jul; 27(20):3319-24. PubMed ID: 19414670
[TBL] [Abstract][Full Text] [Related]
26. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.
Nieuweboer AJ; Smid M; de Graan AM; Elbouazzaoui S; de Bruijn P; Eskens FA; Hamberg P; Martens JW; Sparreboom A; de Wit R; van Schaik RH; Mathijssen RH
Pharmacogenomics J; 2016 Nov; 16(6):519-524. PubMed ID: 26345519
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial.
Ruiz-Pinto S; Martin M; Pita G; Caronia D; de la Torre-Montero JC; Moreno LT; Moreno F; García-Sáenz JÁ; Benítez J; González-Neira A
Pharmacogenet Genomics; 2018 Nov; 28(11):245-250. PubMed ID: 30334909
[TBL] [Abstract][Full Text] [Related]
28. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Lewis LD; Miller AA; Owzar K; Bies RR; Markova S; Jiang C; Kroetz DL; Egorin MJ; McLeod HL; Ratain MJ;
Pharmacogenet Genomics; 2013 Jan; 23(1):29-33. PubMed ID: 23188068
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.
Ando Y; Price DK; Dahut WL; Cox MC; Reed E; Figg WD
Cancer Biol Ther; 2002; 1(6):669-73. PubMed ID: 12642692
[TBL] [Abstract][Full Text] [Related]
30. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
[TBL] [Abstract][Full Text] [Related]
31. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
32. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Kim KP; Ahn JH; Kim SB; Jung KH; Yoon DH; Lee JS; Ahn SH
Cancer Chemother Pharmacol; 2012 May; 69(5):1221-7. PubMed ID: 22271208
[TBL] [Abstract][Full Text] [Related]
33. DMET microarray technology for pharmacogenomics-based personalized medicine.
Burmester JK; Sedova M; Shapero MH; Mansfield E
Methods Mol Biol; 2010; 632():99-124. PubMed ID: 20217574
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
[TBL] [Abstract][Full Text] [Related]
35. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods.
Fernandez CA; Smith C; Yang W; Lorier R; Crews KR; Kornegay N; Hicks JK; Stewart CF; Kawedia JD; Ramsey LB; Liu C; Evans WE; Relling MV; Broeckel U
Clin Pharmacol Ther; 2012 Sep; 92(3):360-5. PubMed ID: 22871999
[TBL] [Abstract][Full Text] [Related]
36. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Lim J; Singh O; Chen X; Tan EH; Lee EJ; Chowbay B
Eur J Clin Pharmacol; 2014 Feb; 70(2):155-66. PubMed ID: 24193570
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
Angelini S; Botticelli A; Onesti CE; Giusti R; Sini V; Durante V; Strigari L; Gentile G; Cerbelli B; Pellegrini P; Sgroi V; Occhipinti M; DI Pietro FR; Rossi A; Simmaco M; Mazzuca F; Marchetti P
Anticancer Res; 2017 May; 37(5):2633-2639. PubMed ID: 28476838
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Bosch TM; Doodeman VD; Smits PH; Meijerman I; Schellens JH; Beijnen JH
Mol Diagn Ther; 2006; 10(3):175-85. PubMed ID: 16771603
[TBL] [Abstract][Full Text] [Related]
40. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
